文献速递消化、代谢与肾脏急症

吲哚美辛单用与联合预防性胰管支架置入预防ERCP后胰腺炎:随机非劣效性试验

Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.
PubMed 文献 · Lancet · 2024-01-11
一句话结论高危患者ERCP后单用直肠吲哚美辛预防胰腺炎不劣于联合支架置入未获证实,结果支持按临床实践指南联合预防性胰管支架置入。

这项在20个转诊中心开展的随机、双盲、非劣效性试验纳入1950例ERCP后胰腺炎高危患者,1:1分配至单用直肠吲哚美辛组或吲哚美辛联合预防性胰管支架组。单用组胰腺炎发生率14.9%(145/975),联合组11.3%(110/975),风险差3.6%(95%CI 0.6-6.6),非劣效性p=0.18,未达到预设的5%非劣效界值。事后意向性治疗分析显示单用组劣于联合组(p=0.011)。支架的相对获益在各亚组中基本一致,在最高危患者中似乎更明显;严重不良事件、ICU入住和住院时间两组无差异。

要点

  • 高危患者ERCP后胰腺炎:单用直肠吲哚美辛组14.9%(145/975) vs 联合预防性胰管支架组11.3%(110/975),风险差3.6%(95%CI 0.6-6.6)。
  • 非劣效性未成立:风险差95%CI上限6.6%超过预设5%非劣效界值,非劣效性p=0.18。
  • 事后意向性治疗分析显示单用吲哚美辛劣于联合预防性支架(p=0.011)。
  • 支架的相对获益在各研究亚组中基本一致,但在胰腺炎最高危患者中似乎更明显。
  • 严重不良事件、ICU入住和住院时间两组无差异。

适用人群与场景

  • 年龄≥18岁、ERCP后胰腺炎高危患者,在美国和加拿大20个转诊中心接受ERCP。

诊断标准与关键阈值

  • 非劣效性判定标准:单用吲哚美辛组减联合支架组胰腺炎风险差的双侧95%CI上限须小于5%(非劣效界值),且在意向性治疗和符合方案人群中均满足。

处置流程与药物剂量

  • 高危患者ERCP后预防胰腺炎:直肠给予吲哚美辛,联合或不联合预防性胰管支架置入;原文未给出吲哚美辛具体剂量。
  • 研究结论支持在高危患者中于直肠吲哚美辛基础上联合预防性胰管支架置入,符合临床实践指南。

研究设计与关键结果

  • 随机、双盲、非劣效性试验,20个转诊中心,1950例ERCP后胰腺炎高危患者,1:1随机分配至单用直肠吲哚美辛组(975例)或吲哚美辛联合预防性胰管支架组(975例)。
  • 主要终点ERCP后胰腺炎:单用组145/975(14.9%) vs 联合组110/975(11.3%),风险差3.6%(95%CI 0.6-6.6),非劣效性p=0.18。
  • 事后意向性治疗分析:单用吲哚美辛劣于联合预防性支架(p=0.011)。
  • 支架的相对获益在各研究亚组中基本一致,但在胰腺炎最高危患者中似乎更明显。
  • 安全性结局(严重不良事件、ICU入住、住院时间)两组无差异。
  • 研究注册号ClinicalTrials.gov NCT02476279;入组时间2015年9月17日至2023年1月25日。

证据类型、等级与局限

  • 证据类型:随机、双盲、非劣效性试验(20个转诊中心)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 高危患者ERCP后预防胰腺炎,单用直肠吲哚美辛不劣于联合预防性胰管支架的策略未获证实(非劣效性p=0.18)。
  • 作者认为,结果支持在高危患者中于直肠吲哚美辛基础上联合预防性胰管支架置入,符合临床实践指南。

指南或共识出处

  • 临床实践指南(原文提及,未给出具体指南名称)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The combination of rectally administered indomethacin and placement of a prophylactic pancreatic stent is recommended to prevent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk patients. Preliminary evidence suggests that the use of indomethacin might eliminate or substantially reduce the need for stent placement, a technically complex, costly, and potentially harmful intervention.

METHODS: In this randomised, non-inferiority trial conducted at 20 referral centres in the USA and Canada, patients (aged ≥18 years) at high risk for post-ERCP pancreatitis were randomly assigned (1:1) to receive rectal indomethacin alone or the combination of indomethacin plus a prophylactic pancreatic stent. Patients, treating clinicians, and outcomes assessors were masked to study group assignment. The primary outcome was post-ERCP pancreatitis. To declare non-inferiority, the upper bound of the two-sided 95% CI for the difference in post-ERCP pancreatitis (indomethacin alone minus indomethacin plus stent) would have to be less than 5% (non-inferiority margin) in both the intention-to-treat and per-protocol populations. This trial is registered with ClinicalTrials.gov (NCT02476279), and is complete.

FINDINGS: Between Sept 17, 2015, and Jan 25, 2023, a total of 1950 patients were randomly assigned. Post-ERCP pancreatitis occurred in 145 (14·9%) of 975 patients in the indomethacin alone group and in 110 (11·3%) of 975 in the indomethacin plus stent group (risk difference 3·6%; 95% CI 0·6-6·6; p=0·18 for non-inferiority). A post-hoc intention-to-treat analysis of the risk difference between groups showed that indomethacin alone was inferior to the combination of indomethacin plus prophylactic stent (p=0·011). The relative benefit of stent placement was generally consistent across study subgroups but appeared more prominent among patients at highest risk for pancreatitis. Safety outcomes (serious adverse events, intensive care unit admission, and hospital length of stay) did not differ between groups.

INTERPRETATION: For preventing post-ERCP pancreatitis in high-risk patients, a strategy of indomethacin alone was not as effective as a strategy of indomethacin plus prophylactic pancreatic stent placement. These results support prophylactic pancreatic stent placement in addition to rectal indomethacin administration in high-risk patients, in accordance with clinical practice guidelines.

FUNDING: US National Institutes of Health.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Elmunzer BJ, Foster LD, Serrano J, et al. Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial. Lancet. 2024. PMID: 38219767. doi:10.1016/S0140-6736(23)02356-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。